Venus Remedies Limited (NSE:VENUSREM)
473.75
-9.65 (-2.00%)
Aug 14, 2025, 3:14 PM IST
Venus Remedies Revenue
Venus Remedies had revenue of 1.32B INR in the quarter ending June 30, 2025, with 21.44% growth. This brings the company's revenue in the last twelve months to 6.71B, up 9.15% year-over-year. In the fiscal year ending March 31, 2025, Venus Remedies had annual revenue of 6.48B with 7.72% growth.
Revenue (ttm)
6.71B
Revenue Growth
+9.15%
P/S Ratio
0.94
Revenue / Employee
5.17M
Employees
1,298
Market Cap
6.31B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 6.48B | 464.37M | 7.72% |
Mar 31, 2024 | 6.01B | 459.40M | 8.27% |
Mar 31, 2023 | 5.56B | -446.71M | -7.44% |
Mar 31, 2022 | 6.00B | 520.57M | 9.50% |
Mar 31, 2021 | 5.48B | 2.07B | 60.90% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 537.77B |
Divi's Laboratories | 96.52B |
Cipla | 274.80B |
Apollo Hospitals Enterprise | 225.51B |
Mankind Pharma | 129.10B |
Zydus Lifesciences | 236.08B |
Fortis Healthcare | 80.94B |
Aurobindo Pharma | 320.25B |
Venus Remedies News
- 3 months ago - Venus Remedies renews GMP certification from Ukraine’s SMDC for Baddi facility - Business Upturn
- 4 months ago - Venus Remedies shares jump 11% after US FDA grants QIDP status to novel antibiotic VRP-034 - Business Upturn
- 4 months ago - Venus Remedies gets US FDA grants QIDP status to novel polymyxin B formulation VRP-034 - Business Upturn
- 6 months ago - Venus Remedies secures exclusive rights for MET-X clinical development in India - Business Upturn
- 7 months ago - Venus Remedies shares surge 10% after EU GMP Certification renewal - Business Upturn
- 7 months ago - Venus Remedies successfully renews EU GMP certification, reinforcing its European market presence - Business Upturn
- 8 months ago - Venus Remedies stock jumps 4% after receiving GMP certification for Antibiotic facility - Business Upturn
- 8 months ago - Venus Remedies shares surge 6% on Pemetrexed marketing authorization in Philippines - Business Upturn